KELLY STRATEGIC CRISPR & GENE EDITING TECHNOLOGY ETF - USD |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.38 USD | -1.60% |
|
-2.45% | -25.75% |
Investment objective
XDNA seeks to track the total return performance, before
fees and expenses, of the Strategic CRISPR & Gene Editing
Technology Index, which measures the performance of
companies that specialize in CRISPR & DNA modification
systems, and technologies, for variety of applications
including basic biological research, development of
biotechnological products, and treatment of diseases as well
as next-generation sequencing that may be used at various
stages of a genome editing workflow.
| Name |
Price
|
Change
|
5d. change
|
1st Jan change
|
Weight
| |
|---|---|---|---|---|---|---|
| 572.4 USD | +0.20% | +0.11% | +7.84% | 11.69% | ||
| 23.6 USD | +1.42% | +17.88% | -22.60% | 11.15% | ||
| 55.89 USD | +1.49% | +4.02% | -10.72% | 8.55% | ||
| 23.13 USD | +1.80% | +7.08% | -15.03% | 8.03% | ||
| 3.77 USD | +3.57% | +0.27% | -34.21% | 6.97% | ||
| 2.87 USD | +2.87% | +40.00% | -14.58% | 4.87% | ||
| 5.67 USD | +0.89% | +8.62% | -44.03% | 4.83% | ||
| 163.8 USD | +1.85% | -2.09% | +5.69% | 4.81% | ||
| 5.59 USD | -0.36% | +30.00% | -36.91% | 4.71% | ||
| 6.41 USD | +4.23% | +3.05% | -54.02% | 4.13% | ||
More news
In partnership with
Description
| US48817R7061 | |
|---|---|
| Total Expense Ratio | 0.78% |
| Asset Class | |
| Sector | |
| Size | |
| Currency | |
| Provider | |
| Underlying | Strategic CRISPR & Gene Editing Technology Index NR - USD |
Features and characteristics
| Jurisdiction | |
| Replication Method | |
| Replication Model | |
| Date of creation |
2022-01-11
|
| Dividend Policy | |
| Geographical Focus |
AuM evolution ( 2023-10-30 )
| AuM (EUR) | 2 M€ |
|---|---|
| AuM 1M | 2 M€ |
| AuM 3 months | 2 M€ |
| AuM 6 months | 2 M€ |
| AuM 12 months | 5 M€ |
- Stock Market
- ETF
- XDNA ETF
